Allogene Therapeutics Sees Long-Term Potential Despite Short-Term Losses of -6.90% Over One Month
April 25, 2023
Trending News ☀️
Allogene Therapeutics ($NASDAQ:ALLO) Inc. is a publicly traded biotechnology company located in California. Recently, the company’s stock price has seen a decrease of -6.90% in the last month. Despite this short-term loss, Allogene Therapeutics Inc. appears to have a positive long-term outlook. During its last trading session, the company had 2.38 million shares traded, and its beta was recorded at 0.76. Analysts have pointed out that Allogene Therapeutics Inc. has strong fundamentals which promise a potential upside potential in the long run. For example, its pipeline consists of six clinical programs, which make up its most promising products. The company also has a number of collaborations with other biopharmaceutical companies, giving them access to innovative technologies and resources. These factors have led to the company’s positive long-term outlook despite its recent losses over the past month.
However, due to its strong fundamentals and collaborations with other biopharmaceutical companies, the company remains optimistic about its long-term potential and remains optimistic about their future performance.
Market Price
Allogene Therapeutics Inc. has been making headlines lately, as their stock price suffered a -6.90% loss over the past month. The company is focused on developing next-generation engineered cell therapies to treat cancer, and has already seen success in clinical trials. With the increasing demand for immunotherapy treatments, Allogene Therapeutics Inc. remains optimistic about their future, and is confident that their efforts will continue to pay off in the long run. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Allogene Therapeutics. More…
| Total Revenues | Net Income | Net Margin |
| 0.24 | -332.63 | -136885.6% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Allogene Therapeutics. More…
| Operations | Investing | Financing |
| -220.52 | 106.16 | 2.95 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Allogene Therapeutics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 817.08 | 151.21 | 4.61 |
Key Ratios Snapshot
Some of the financial key ratios for Allogene Therapeutics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| – | – | -138044.9% |
| FCF Margin | ROE | ROA |
| -92884.8% | -29.8% | -25.7% |
Analysis
At GoodWhale, we have conducted an extensive analysis and review of ALLOGENE THERAPEUTICS’ financials and overall business. Based on our Risk Rating assessment, we have determined that ALLOGENE THERAPEUTICS is a medium risk investment in terms of financial and business aspects. We have also detected 3 risk warnings in the balance sheet, cashflow statement, and financial journal. If you would like to know more about these risk warnings, you can register with us to gain access to detailed information. More…
Peers
Allogene Therapeutics Inc is a clinical-stage biopharmaceutical company, engaged in the development of allogeneic CAR T cell therapies for the treatment of cancer. Allogene Therapeutics Inc’s competitors are Arvinas Inc, Nascent Biotech Inc, JW (Cayman) Therapeutics Co Ltd.
– Arvinas Inc ($NASDAQ:ARVN)
Arvinas Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing proteolysis-targeting chimeras (PROTACs) to degrade and control proteins that drive disease. Arvinas has a market cap of 2.29B as of 2022 and a Return on Equity of -32.37%. The company’s lead product candidate, ARV-110, is in clinical development for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Arvinas is also developing ARV-471 for the treatment of HER2-positive breast cancer and ARV-825 for the treatment of urothelial cancer.
– Nascent Biotech Inc ($OTCPK:NBIO)
Nascent Biotech Inc is a clinical-stage biopharmaceutical company with a focus on developing monoclonal antibodies to treat various cancers. The company’s market cap is 26.93M as of 2022 and its ROE is 55.87%. Nascent Biotech Inc is a relatively small company, but it has shown impressive growth potential. The company’s focus on developing monoclonal antibodies to treat cancer is a promising area of research that could lead to breakthrough treatments for this devastating disease.
– JW (Cayman) Therapeutics Co Ltd ($SEHK:02126)
JW (Cayman) Therapeutics Co Ltd is a clinical stage biopharmaceutical company focused on developing and commercializing novel cancer immunotherapies. The company’s lead product candidate, JTX-2011, is a first-in-class, off-the-shelf, multi-antigen targeted T cell therapy being evaluated in a Phase 1/2 clinical trial for the treatment of solid tumors. JW (Cayman) Therapeutics Co Ltd has a market cap of 1.32B as of 2022, a Return on Equity of -19.61%.
Summary
Allogene Therapeutics‘ stock has dropped by nearly -6.90% in one month, yet the long-term outlook appears positive. The stock saw strong trading activity with 2.38 million shares traded and a beta of 0.76. Investors should keep an eye on Allogene Therapeutics’ stock and consider executing a buy-in strategy in the long-term, as the company appears to be well-positioned to deliver returns.
Analysts should consider the short-term performance of the stock, as well as its current valuation when investing in Allogene Therapeutics. Long-term investors should assess the company’s competitive advantages, growth potential, and financials before making any decisions.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
